Skip to main content

Year: 2025

Form 8.3 – [IDOX PLC – Opening Disclosure – 28 10 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree IDOX PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: IDOX PLC AS AN ASSOCIATE OF THE CANACCORD...

Continue reading

Form 8.3 – [NCC GROUP PLC – 28 10 2025] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree NCC GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025

JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, November 12, 2025. Conference Call Information Date: Wednesday, November 12, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560 Conference ID: 13751389 Webcast Link:. https://viavid.webcasts.com/starthere.jsp?ei=1706029&tp_key=b177e95e36....

Continue reading

Kirby Corporation Announces 2025 Third Quarter Results

Third quarter 2025 earnings per share of $1.65, up 6% year-over-year Inland marine third quarter impacted by lower utility, averaging in the mid-80% range for the quarter with improvement into the 85-90% range expected and already seen in the fourth quarter Steady market conditions in coastal marine with operating margins improving to around 20% Power generation revenue increased 24% sequentially and 56% year-over-year, helping to drive distribution and services margins to 11% Kirby repurchased 1,314,009 shares at an average price of $91.30 for $120.0 million in the third quarter and an additional 428,955 shares at an average price of $84.13 for $36 million so far in the fourth quarterHOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) — Kirby Corporation (“Kirby”) (NYSE: KEX) today announced net earnings attributable to Kirby for the third...

Continue reading

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

        ― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to provide data from the 20 mg dose cohort by year-end ― ― Ended Q3 2025 with $200.6 million in cash, cash equivalents, and marketable securities; cash runway into 2028 ― CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the third quarter of 2025 and provided a business update. “We are extremely pleased with the compelling data from the 12 mg dose cohort...

Continue reading

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial ResultsThird quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a 6.0% increase over the second quarter of 2025. For the third quarter of 2025, gross margin was 76.6%, up from 74.9% for the third quarter of 2024, and up from 74.2% in the second quarter of 2025. Net income for the quarter was $0.7 million, or $0.01 per share, compared to a Net loss of $1.9 million, or $0.04...

Continue reading

Coastal Financial Corporation Announces Third Quarter 2025 Results

EVERETT, Wash., Oct. 29, 2025 (GLOBE NEWSWIRE) — Coastal Financial Corporation (Nasdaq: CCB) (the “Company”, “Coastal”, “we”, “our”, or “us”), the holding company for Coastal Community Bank (the “Bank”), through which it operates a community-focused bank segment (“community bank”) with an industry leading banking as a service (“BaaS”) segment (“CCBX”), today reported unaudited financial results for the quarter ended September 30, 2025, including net income of $13.6 million, or $0.88 per diluted common share, compared to $11.0 million, or $0.71 per diluted common share, for the three months ended June 30, 2025 and $13.5 million, or $0.97 per diluted common share, for the three months ended September 30, 2024. Management Discussion of the Third Quarter...

Continue reading

The Vita Coco Company Reports Strong Third Quarter 2025 Financial Results and Raises Full Year Guidance

Net Sales Increased 37% to $182 million driven by Vita Coco Coconut Water growth of 42% Net Income Increased $5 million to $24 million and Non-GAAP Adjusted EBITDA1 Increased $9 million to $32 million Company Raises Full Year Net Sales and Adjusted EBITDA Guidance NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the third quarter ended September 30, 2025. Third Quarter and Year-to-Date 2025 Highlights Compared to Prior Year PeriodNet sales were $182 million an increase of 37% in the third quarter and $482 million year-to-date an increase of 24%. Vita Coco Coconut Water net sales grew 42% in the third quarter and 31% year-to-date. Gross profit was $69 million...

Continue reading

The Chefs’ Warehouse Reports Third Quarter 2025 Financial Results

RIDGEFIELD, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States, the Middle East, and Canada, today reported financial results for its third quarter ended September 26, 2025. Financial highlights for the third quarter of 2025:Net sales increased 9.6% to $1,021.3 million for the third quarter of 2025 from $931.5 million for the third quarter of 2024. GAAP net income was $19.1 million, or $0.44 per diluted share, for the third quarter of 2025 compared to $14.1 million, or $0.34 per diluted share, in the third quarter of 2024. Adjusted net income per share1 was $0.50 for the third quarter of 2025 compared to $0.36 for the third quarter of 2024. Adjusted EBITDA1 was $65.1 million for the third quarter of...

Continue reading

Oatly Reports Third Quarter 2025 Financial Results

MALMÖ, Sweden, Oct. 29, 2025 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly”, the “Company” or the “Group”), the world’s original and largest oat drink company, today announced financial results for the third quarter ended September 30, 2025. Jean-Christophe Flatin, Oatly’s CEO, commented, “I am proud to report that we drove profitable growth in the quarter, with solid constant currency revenue growth and positive adjusted EBITDA. Achieving this milestone reflects the disciplined, strategic actions we have taken over the past three years to strengthen the foundation of our entire business. While we are proud of this achievement, we know that profitable growth is a milestone and not the finish line. We see significant potential ahead of us, and we are confident that we are taking the right steps to drive durable, scalable,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.